key: cord-0788370-em80y4m0 authors: Qu, Panke; Faraone, Julia N.; Evans, John P.; Zou, Xue; Zheng, Yi-Min; Carlin, Claire; Bednash, Joseph S.; Lozanski, Gerard; Mallampalli, Rama K.; Saif, Linda J.; Oltz, Eugene M.; Mohler, Peter J.; Gumina, Richard J.; Liu, Shan-Lu title: Differential Evasion of Delta and Omicron Immunity and Enhanced Fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants date: 2022-05-17 journal: bioRxiv DOI: 10.1101/2022.05.16.492158 sha: ffbdad9428611958cda6140debba038c1b4fd7e0 doc_id: 788370 cord_uid: em80y4m0 The rising case numbers of the SARS-CoV-2 Omicron BA.4, BA.5, and BA.2.12.1 subvariants has generated serious concern about the course of the pandemic. Here we examine the neutralization resistance, infectivity, processing, and fusogenicity of spike from the BA.4/5 and BA.2.12.1 SARS-CoV-2 variants compared with other Omicron subvariants and Delta. Critically, we found that the new Omicron subvariants BA.4/5 and BA.2.12.1 were more resistant to neutralization by mRNA-vaccinated and boosted health care worker sera and Omicron-BA.1-wave patient sera than were the BA.1 and BA.2 variants. Interestingly, Delta-wave patient sera neutralized more efficiently against not only Delta but also BA.4/5 and BA.2.12.1 variants that also contain substitutions at position L452, similar to Delta. The BA.4/5 and BA.2.12.1 variants also exhibited higher fusogenicity, and increased spike processing, dependent on the L452 substitution. These results highlight the key role of the L452R and L452Q mutations in BA.4/5 and BA.2.12.1 subvariants. The rising frequency of several SARS-CoV-2 Omicron subvariants, especially BA.4/5 and 56 BA.2.12.1, has reignited the new concern about further escape from vaccine-and infection-57 We next determined the propensity for the Omicron subvariant S proteins to mediate 182 membrane fusion. HEK293T-ACE2 cells were co-transfected with the various S protein constructs 183 and GFP and incubated for 24 and 48 hours, and cell-cell fusion was visualized using 184 fluorescence microscopy with size of syncytia formation being quantified ( Fig. 3A and 3B; Fig. 185 S3). Consistent with our previous data, BA.1 showed markedly lower fusion than the ancestral 186 D614G (4.7-fold) and Delta (11.3-fold) ( Fig. 3B ) (Zeng et al., 2021a) . Fusion by BA.2 was 187 observably higher than BA.1 with a 1.5-fold increase (Fig. 3B) . While still much lower than fusion 188 mediated by Delta (5.2-fold lower for BA.4/5, 5.6-fold lower for BA.2.12.1), the newly emerged 189 Omicron subvariants BA.4/5 and BA.2.12.1 exhibited a higher propensity for fusion, with an 190 average syncytia area 2.1-fold and 1.4-fold higher than BA.1 and BA.2, respectively ( Fig. 3A and 191 3B ). This phenotype was likely attributed to the L452R or L452Q mutation present in BA.4/5 or 192 BA.1.12.1, as demonstrated by the 2.0-fold increase relative to BA.1 and 1.4-fold increase relative 193 to BA.2 for the BA.2_L452Q single mutant (Fig. 3B) . Interestingly, BA.2_S704L displayed 194 decreased fusogenicity 1.5-fold lower than BA.2 (Fig. 3B) . 195 We next examined S expression on the surface of viral producer cells using flow 196 cytometry. Compared to D614G and Delta, BA.1 and BA.2 exhibited slightly higher expression 197 compared to D614G, i.e. 1.5-fold and 1.4-fold relative to D614G, respectively ( Fig. 3C and 3D) . 198 The two new subvariants, i.e., BA.4/5 and BA.2.12.1, exhibited comparable surface expression, 199 with 1.5-fold and 1.4-fold higher surface expression than D614G, respectively (Fig. 3D) . The BA.2 200 single mutants, i.e., BA.2_L452Q and BA.2_S704L, both exhibited slightly reduced surface 201 expression compared to BA.4/5 and BA.2.12.1 (Fig 3C and 3D) . 202 203 Mutation of L452 to R or Q in BA.4/5 or BA.2.12.1 increases spike processing compared to 204 We further sought to characterize the processing of the above Omicron subvariant S 206 proteins in cell lysate of virus-producing cells as well as purified viral particles. Lysates from 207 HEK293T cells used to produce the pseudotyped virus were collected and probed for S1 subunit 208 expression versus the full-length S. We have previously demonstrated that BA.1 spike exhibits a 209 lower propensity for furin cleavage, as shown by the reduced ratio of S1/S, in both lysate and 210 purified virions (Zeng et al., 2021a) . Here we found that processing of BA.2 S remained 211 comparable to BA.1, but more processing was observed for BA.4/5 and BA.2.12.1, with a 1.4-fold 212 and 1.2-fold higher compared to D614G, respectively (Fig. 3E) . A similar conclusion could be 213 drawn from the analysis of purified viral particle, wherein BA.4/5, BA.2.12.1 and two single 214 mutants all demonstrated the increased S1 signals in purified virions compared to BA.2 -given 215 similar intensity of p24 in the virions (Fig. 3F) . In accordance with the fusion results, the increased 216 S processing phenotype in BA.4/5 and BA.2.12.1 was likely attributed to the L452R or L452Q 217 mutation in their receptor binding domain, given that BA.2_L452Q single mutant showed 218 increased S processing in both virus-producing cells and produced virions (Fig. 3E) . Of note, the 219 processing of BA.2_S704L was slightly reduced in the cells, though not obviously in the virions, 220 ruling out its likely contribution to the BA.2.12.1 phenotype, which was also consistent with its 221 reduced fusogenicity compared to BA.2 (Fig. 3A, 3B, and 3E) . The authors declare no competing interests. 299 replicates. Bars in (B) and (D) represent means ± standard deviation, and significance was 347 determined by one-way ANOVA with Bonferroni's multiple testing correction. Throughout, p-values are represented as * p < 0.05, * * p < 0.01, ***p < 0.001, ****p < 0.0001, ns, not significant. 349 (E) Pseudotyped virus-producing cells were lysed and pseudotyped viruses were purified by 350 ultracentrifugation (F) and blots were probed for S1 subunit, HIV-1 capsid (p24), and GAPDH 351 loading control; S cleavage was quantified using NIH ImageJ and by setting the ratio of S1/S of 352 D614G to 1.0 (E) and by setting the S1/p24 of D614G to 1.0 for (F). 353 Further information and requests for resources and reagents should be directed to the lead 357 contact, Dr. Shan-Lu Liu (liu.6244@osu.edu). 358 359 Plasmids generated in this study are available upon request made to the lead contact. 361 362 Data and code availability 363 • NT50 values and de-identified patient information will be deposited to the National Cancer 364 Institute SeroNet Coordinating Center. Additionally, NT50 values and de-identified patient 365 information reported in this paper will be shared by the lead contact upon request. 366 • This paper does not report original code. 367 • Any additional information required to reanalyze the data reported in this paper is available Pseudotyped lentivirus neutralization assays were performed as previously described (Evans et were analyzed using FlowJo v7.6.5 (Ashland, OR). 451 HEK293T-ACE2 cells were co-transfected with variant spikes of interest and a GFP expression 453 plasmid. Cells were incubated for 24 and 48 hours and images were taken at 4x magnification on 454 a Leica DMi8 confocal microscope. Three images were taken for each sample and used to 455 quantify total area of fused cells (syncytia) using the Leica microscope analysis software. A 456 representative image was selected for each. 457 Purification of pseudotyped particles was performed using ultracentrifugation through a 20% 459 sucrose cushion. The resulting pellet was resuspended in SDS-PAGE loading buffer in 460 preparation for western blotting. Additionally, the cell lysate of virus producing cells was collected 461 72 hours post transfection through lysis with RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 462 mM EDTA, Nonidet P-40, 0.1% SDS) supplemented with protease inhibitor (Sigma, P8340) on 463 ice for 30 min Purification and lysate samples were run on a 10% acrylamide SDS-PAGE gel and 464 transferred to a PVDF membrane. Membranes were blotted with anti-S1 (Sino Biological, 40150-465 T62), anti-p24 (Abcam, ab63917; NIH ARP-1513), and anti-GAPDH (Santa Cruz Biotech, sc-466 47724). Anti-mouse-IgG-Peroxidase (Sigma, A5278) and anti-rabbit-IgG-HRP (Sigma, A9169) 467 were used as secondary antibodies accordingly. Blots were imaged with Immobilon Crescendo 468 Western HRP substrate (Millipore, WBLUR0500) on a GE Amersham Imager 600. 469 All statistical analysis was performed using GraphPad Prism 9 and are described in the figure 472 legends. NT50 values were determined by least-squares fit non-linear regression in GraphPad 473 Prism 9. Throughout, n refers to subject number and bars represent either ± standard deviation 474 (Fig 1A and B, Fig 2B and D) or geometric means ± 95% confidence intervals (Fig 1C and E, 475 Fig2A, C, D, F and Fig S2I and J) . Generally, comparisons between multiple groups were made 476 using a one-way repeated measures ANOVA with Bonferroni post-test (Fig 1A, B, C and E, 2A 477 and D, 3B and D). Comparisons between treatment groups were made using a two-way repeated 478 measures ANOVA with Bonferroni post-test (Fig 2C and F, Fig S2I and J) . Comparisons between 479 two-groups were made using a paired two-tailed student's t-test with Welch's correction (Fig S2A-480 H) . Analysis of the influence of sex on neutralization capacity could not be performed due to small 481 sample size-confounding variables including vaccination status, vaccine type, and time since 482 vaccination would skew such an analysis. Infectivity was quantified using luminescence readings 483 measured by a BioTek Cytation5 plate reader. Three readings were taken and averaged for each 484 of the three replicates. Quantification of syncytia was performed using the Leica DMi8 confocal 485 microscope analysis software to identify the edges of syncytia and quantify area. Surface staining 486 was quantified with a Life Technologies Attune NxT flow cytometer. Results were processed using 487 FlowJo v7.6.5. Western Blot quantification was performed using NIH ImageJ and by setting the 488 ratio of S1/S and S1/p24 of BA.2 to 1.00. p24 S1 S S1/p24 New SARS-CoV-2 Variants -Clinical, Public 492 Health, and Vaccine Implications Drugs that inhibit TMEM16 proteins block 496 SARS-CoV-2 spike-induced syncytia COVID-19: Omicron -the latest, the least virulent, but probably not the last 499 variant of concern of SARS-CoV-2 SARS-CoV-2 Variant Classifications and 502 Definitions Variant Proportions Culture and identification of a "Deltamicron" SARS-CoV-506 2 in a three cases cluster in southern France Loss of Neutralizing Antibody Response to mRNA Vaccination against SARS-CoV-2 2 510 Variants: Differing Kinetics and Strong Boosting by Breakthrough Infection 3 4 5 Neutralization of SARS-CoV-2 Omicron Sub-lineages Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over 517 time and are boosted by breakthrough infection Neutralization of the SARS-CoV-2 Deltacron and BA.3 520 Variants Cell-free metabolic 522 engineering promotes high-level production of bioactive Gaussia princeps luciferase The Omicron variant is highly Scobie Hospitalizations, and Deaths, by Vaccination Status -13 U.S. Jurisdictions SARS-CoV-2 579 variants of concern are emerging in India Occurrence and significance 583 of Omicron BA.1 infection followed by 1 BA.2 reinfection 2 3 Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants Emergence and rapid 590 transmission of SARS-CoV-2 B.1.1.7 in the United States Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against 594 Omicron SARS-CoV-2. Cell Host and Microbe Virological characteristics of SARS-CoV-2 BA.2 variant Comparable Neutralization of the SARS-CoV-2 Omicron 601 BA.1 and BA.2 Variants Authors for Print Edition Structural and Functional Analysis of the 605 D614G SARS-CoV-2 Spike Protein Variant Neutralizing antibody against SARS-CoV-2 spike in 609 COVID-19 patients, health care workers, and convalescent plasma donors Neutralization and Stability of SARS-CoV-2 Omicron 613 Variant Impaired neutralizing antibody response 616 to COVID-19 mRNA vaccines in cancer patients Neutralization of SARS-CoV-2 Variants of Concern 620 Harboring Q677H SARS-CoV-2 spreads through cell-to-cell transmission Structural and functional characteristics of SARS-CoV-2 Omicron 626 subvariant BA.2 spike Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell-cell 629 fusion, and neutralization sensitivity SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte 633 elimination Evidence of escape of SARS-CoV-2 variant 637 B.1.351 from natural and vaccine-induced sera